pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,318 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1024Endpoints775BioPharma Dive297BioSpace214Fierce Biotech203onclive165raps74globenewswire health
therapy area
allOncology6024Rare Disease1430Cardiology1089Hematology1024Immunology997Vaccines901Pulmonology
  • FDA approves Regeneron's hearing loss gene therapy Otarmeni
    Regeneron has won the first-ever FDA approval for a gene therapy to treat a rare type of inherited hearing loss, and the company plans to offer the treatment for free in the US, though that ...
    Endpoints · 3mo ago↗ source
  • Substance use disorder biotech Tempero to close after earlier 'serious' safety event
    Tempero Bio, a drug developer that had big ambitions to shake up the treatment of substance use disorders, is winding down operations, Endpoints News has learned. The shutdown comes after a "seriou…
    Endpoints · 3mo ago↗ source
  • Post-Hoc Live: MAHA, the new Trump CDC pick and RFK's vaccine agenda
    MAHA’s sway over HHS could face a fresh test now that President Trump has a new pick for CDC director: Erica Schwartz, a former deputy surgeon general. The position has been empty ...
← prev
page 53 of 53
next →
73
fda recalls47
fda medwatch37
fda press28
899
Psychiatry & CNS712
Ophthalmology420
Endocrinology & Metabolism380
Pain372
Infectious Disease353
Endpoints · 3mo ago
↗ source
  • Novartis' radioligand therapy Lutathera could soon face generic competition
    The radioligand field is on the cusp of a major competitive moment, as a rival looks to bring the first generic to a market that’s been dominated by Novartis. Radioligand therapy aims to bring the ...
    Endpoints · 3mo ago↗ source
  • David Reese to retire from Amgen
    Longtime Amgen leader David Reese is retiring at the end of June, Amgen announced Wednesday evening. Reese, 63, currently serves as chief technology officer, a role he created at Amgen in 2023 ...
    Endpoints · 3mo ago↗ source
  • The Godmother of Silicon Valley is helping launch an AI healthcare residency program
    Esther Wojcicki wants to help healthcare startup co-founders get along. That might seem simple, but co-founder disagreements are a big contributor to startups falling apart, she said. She’s got the…
    Endpoints · 3mo ago↗ source
  • Novo's pill for kids; Altimmune’s $225M offering; Merck teams with Google Cloud
    Novo Nordisk’s GLP-1 pill works in kids with diabetes: Type 2 diabetes patients aged 10 to 17 who took Rybelsus for about six months had a statistically significant 0.83% cut in their blood sugar l…
    Endpoints · 3mo ago↗ source
  • Amneal to buy a biosimilar company; Samsung Bio workers protest
    Plus, news about Avonik, a supply chain transparency bill and Nucleus RadioPharma: 💰 Amneal Pharmaceuticals to acquire biosimilar maker for $375M upfront: The generics and specialty drugmaker is s…
    Endpoints · 3mo ago↗ source
  • Endpoints wins Neal Awards for Trump and gene editing coverage, JPM event
    Endpoints News was recognized with three 2026 Neal Awards for its coverage of the drug industry's relationship with the Trump administration, a three-part series on the future of CRISPR gene editin…
    Endpoints · 3mo ago↗ source
  • Gravity Rail raises $2.75M from Redesign Health for AI patient communication
    A startup that helps healthcare providers handle calls, texts and follow-ups with patients using AI has raised seed funding, Endpoints News learned exclusively. Gravity Rail handles the process of…
    Endpoints · 3mo ago↗ source
  • Roche says its investigational breast cancer pill could outsell Herceptin
    Roche still has high sales hopes for its breast cancer pill giredestrant despite the drug’s failure in a first-line trial earlier this year. CEO Thomas Schinecker said Thursday that the drug could ...
    Endpoints · 3mo ago↗ source
  • Sanofi defends Garijo appointment, says it is 'fully committed' to immunology
    Sanofi’s first-quarter earnings call with the media on Thursday was an exercise in redirecting the narrative before its new CEO steps in next week. CFO François-Xavier Roger defended the company’s…
    Endpoints · 3mo ago↗ source
  • OpenAI's head of health lays out the AI giant’s healthcare ambitions
    OpenAI is launching ChatGPT for Clinicians, a free tool for doctors, nurse practitioners, physician assistants and pharmacists. It’s the latest product the AI giant has launched within healthcare,…
    Endpoints · 3mo ago↗ source
  • AbbVie's $1.4B North Carolina manufacturing site to finish during Trump's term
    AbbVie has provided new details about its $100 billion pledge to the US, budgeting $1.4 billion for its first manufacturing campus in North Carolina. Construction of the 185-acre campus in Durham,…
    Endpoints · 3mo ago↗ source
  • BridgeBio’s oncology spinoff swaps out CEOs as it seeks to accelerate KRAS work
    BridgeBio Oncology Therapeutics is replacing CEO Eli Wallace, putting its CSO Pedro Beltran in the role, and making board member Neil Kumar executive chairman. The changes come as there’s been grow…
    Endpoints · 3mo ago↗ source
  • Pharma-backed petition calls on FDA to reform release of drug rejection letters
    The FDA for the first time is facing pharma-backed criticism of its new practice of publicly releasing partially redacted drug rejection letters. The law firm Covington & Burling, on behalf of an u…
    Endpoints · 4mo ago↗ source
  • Fierce Biotech Layoff Tracker 2026: Kolon cuts workforce after ph. 3 fail; Sanofi sheds 229 staffers
    As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.
    Fierce Biotech · 8mo ago↗ source
  • Fierce Biotech Fundraising Tracker '26: Abcuro secures $66M; InduPro assembles $77M
    The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.
    Fierce Biotech · 8mo ago↗ source